Last reviewed 2026-04-20 · How we verify

Ketanol (KEBUZONE)

Phase 2 active Small molecule

Ketanol (generic name: KEBUZONE) is a kebuzone drug. It is currently in Phase 2 development.

Ketanol is thought to work by interacting with a specific molecular target to produce its therapeutic effect.

Ketanol, also known as Kebuzone, is a small molecule drug in the kebuzone class. Its exact target and mechanism of action are unknown, but it is being developed for an unspecified indication. The commercial status of Ketanol is unclear, and it is not known whether it is patented or available as a generic medication. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also lacking. As a result, key safety considerations and approved indications for Ketanol remain unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	KEBUZONE
Drug class	kebuzone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and the key to unlocking the right response is a specific molecule. Ketanol is like a key that fits into one of these locks, allowing the cell to respond in a way that treats the underlying condition. However, the exact lock and key mechanism of Ketanol is still not fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ketanol CI brief — competitive landscape report
Ketanol updates RSS · CI watch RSS

Frequently asked questions about Ketanol

What is Ketanol?

Ketanol (KEBUZONE) is a kebuzone drug.

How does Ketanol work?

Ketanol is thought to work by interacting with a specific molecular target to produce its therapeutic effect.

What is the generic name of Ketanol?

KEBUZONE is the generic (nonproprietary) name of Ketanol.

What drug class is Ketanol in?

Ketanol belongs to the kebuzone class. See all kebuzone drugs at /class/kebuzone.

What development phase is Ketanol in?

Ketanol is in Phase 2.

Drug class: All kebuzone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing